Comparative Pharmacology
Head-to-head clinical analysis: LUMATEPERONE versus UZEDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMATEPERONE versus UZEDY.
LUMATEPERONE vs UZEDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lumateperone is an atypical antipsychotic with a unique mechanism of action: it acts as a 5-HT2A receptor antagonist, a dopamine D2 receptor antagonist, and a serotonin reuptake inhibitor. It also modulates glutamate via enhanced AMPA and NMDA receptor activity.
Atypical antipsychotic; antagonist at dopamine D2 and serotonin 5-HT1A/5-HT2A receptors; partial agonist at serotonin 5-HT1A receptors
42 mg orally once daily, taken with food and at least 240 mL of water, with a titration schedule: 42 mg daily for 7 days, then 21 mg twice daily thereafter.
UZEDY (risperidone) extended-release injectable suspension: 75 mg, 100 mg, 150 mg, or 200 mg IM gluteal injection every 2 weeks after a single oral dose of 2 mg risperidone for 2 days; or 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, or 150 mg IM every 4 weeks after oral overlap for 2 days. Oral risperidone may be omitted if patient is stable on oral risperidone 2 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 13 hours in the plasma, supporting once-daily dosing. Steady state is reached within 5–7 days.
Terminal half-life approximately 30 days (range 23–37 days) after subcutaneous injection, supporting monthly dosing.
Approximately 80% of the dose is excreted in feces (as unchanged drug and metabolites) and about 11% in urine. Less than 1% is excreted as unchanged lumateperone in urine.
Primarily renal: 80% as metabolites, 1% unchanged. Biliary/fecal: 20%.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic